ConductScience.org, home

Paper16100034

Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine.

Abidi P and 3 others. Arterioscler Thromb Vasc Biol, 2005. Cited by 142 papers, by iCite.

Cite this record

ConductScience Library. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Papers, record 16100034. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16100034

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine.
PubMed
Journal
Arterioscler Thromb Vasc Biol
PubMed
Year
2005
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, Non-P.H.S.
PubMed
Citations, by iCite
142
iCite
Relative citation ratio, by iCite
3.49
iCite
Revised in PubMed
2014-11-20
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Abidi PParveen
2Zhou YYue
3Jiang JDJian-Dong
4Liu JJingwen

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
BerberineMajor topic
Extracellular Signal-Regulated MAP KinasesMajor topic
Herbal MedicineMajor topic
HypercholesterolemiaMajor topic
MAP Kinase Signaling SystemMajor topic
Receptors, LDLMajor topic
3' Untranslated Regions
Bile Acids and Salts
Carcinogens
Carcinoma, Hepatocellular
Cell Line, Tumor
Cytomegalovirus
Humans
In Vitro Techniques
Liver Neoplasms
Plasmids
Promoter Regions, Genetic
RNA Stability
RNA, Messenger
Tetradecanoylphorbol Acetate

Source PubMed

Download CSV of topics

Cited by65

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 142 citations.

PMIDTitleJournalYearIn PapersSource
42943269Combination Therapy Potential of HTD1801 (Berberine Ursodeoxycholate) in MASLD/MASH and Cardiovascular-Kidney-Metabolic Disease: A Narrative Review.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42943269PubMed
41745758Microcystin-LR Drives Early NAFLD Pathogenesis via Hepatic Cholesterol Accumulation: Dysregulation of Ldlr and Abcg1 Expression Uncoupled from Srebp2.Toxins (Basel)2026https://conductscience.org/library/papers/41745758PubMed
40881894Red yeast rice with monacolin K for the improvement of hyperlipidemia: A narrative review.World J Clin Cases2025https://conductscience.org/library/papers/40881894PubMed
40506769Berberine as a multi-target therapeutic agent for obesity: from pharmacological mechanisms to clinical evidence.Eur J Med Res2025https://conductscience.org/library/papers/40506769PubMed
40278960Obesity: pathophysiology and therapeutic interventions.Mol Biomed2025https://conductscience.org/library/papers/40278960PubMed
39021815
Herbal Products as Complementary or Alternative Medicine for the Management of Hyperglycemia and Dyslipidemia in Patients with Type 2 Diabetes: Current Evidence Based on Findings of Interventional Studies.
J Nutr Metab2024https://conductscience.org/library/papers/39021815PubMed
38034996Efficacy and underlying mechanisms of berberine against lipid metabolic diseases: a review.Front Pharmacol2023https://conductscience.org/library/papers/38034996PubMed
37346213Berberine for Adjunct/Alternative Treatment of Dyslipidemia: A Literature Review.Cureus2023https://conductscience.org/library/papers/37346213PubMed
37240523Lipid-Lowering Nutraceuticals for an Integrative Approach to Dyslipidemia.J Clin Med2023https://conductscience.org/library/papers/37240523PubMed
36432457Nutraceutical Approaches to Dyslipidaemia: The Main Formulative Issues Preventing Efficacy.Nutrients2022https://conductscience.org/library/papers/36432457PubMed
36381647Berberine: Ins and outs of a nature-made PCSK9 inhibitor.EXCLI J2022https://conductscience.org/library/papers/36381647PubMed
35941413Modulatory effect of berberine on plasma lipoprotein (or lipid) profile: a review.Mol Biol Rep2022https://conductscience.org/library/papers/35941413PubMed
35744831Expatiating the Pharmacological and Nanotechnological Aspects of the Alkaloidal Drug Berberine: Current and Future Trends.Molecules2022https://conductscience.org/library/papers/35744831PubMed
35337067Acanthaster planci Inhibits PCSK9 Gene Expression via Peroxisome Proliferator Response Element (PPRE) and Activation of MEK and PKC Signaling Pathways in Human Liver Cells.Pharmaceuticals (Basel)2022https://conductscience.org/library/papers/35337067PubMed
35334087Hypertension and Dyslipidemia Combined Therapeutic Approaches.High Blood Press Cardiovasc Prev2022https://conductscience.org/library/papers/35334087PubMed
34345932Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?Curr Atheroscler Rep2021https://conductscience.org/library/papers/34345932PubMed
33863898Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome.NPJ Biofilms Microbiomes2021https://conductscience.org/library/papers/33863898PubMed
33019656Triciribine Engages ZFP36L1 and HuR to Stabilize LDLR mRNA.Molecules2020https://conductscience.org/library/papers/33019656PubMed
32789786Promising Anti-atherosclerotic Effect of Berberine: Evidence from In Vitro, In Vivo, and Clinical Studies.Rev Physiol Biochem Pharmacol2020https://conductscience.org/library/papers/32789786PubMed
31915510The Use of Nutraceuticals to Counteract Atherosclerosis: The Role of the Notch Pathway.Oxid Med Cell Longev2019https://conductscience.org/library/papers/31915510PubMed

See all 65 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
LDLR3949PubTator's text mininghttps://conductscience.org/library/genes/3949NCBI Gene
MAPK15594PubTator's text mininghttps://conductscience.org/library/genes/5594NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/16100034

GET https://conductscience.org/api/papers/v1/16100034/cited_by?page=2